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Abstract: 
Glimepiride (GMP) is poorly water soluble drug, so solubility is the main constraint for its oral 
bioavailability. Because, poor aqueous solubility and slow dissolution rate of the glimepiride lead 
to irreproducible clinical response or therapeutic failure in some cases due to sub therapeutic 
plasma drug levels. In this study, binary and ternary solid dispersion of glimepiride were 
prepared withpoloxamer 407, polyethylene glycol 6000 (PEG 6000), polyethylene glycol 4000 
(PEG 4000), and eudragit at different weight ratios using the solvent evaporation and melting 
method. Fusion method of thepoloxamer 407 and Eudragit with glimepiride at different ratios 
were also used. It was found the drug was released 0.46% after 5 minutes and only 15.83% 
within 60 minutes from active glimepiride on the other hand the release pattern of glimepiride 
from the binary formulation containing PEG 4000 in 1:5 (Formulation coding: G5) showed the 
best result. It was found that the ternary different SD formulation containing ( 
PEG4000:Glimepiride:Povidon) In ratio 1:1:0.25(Formulation coding were : G13) showed the 
best result. It was also studied that the release kinetics of glimepiride of different SD formulation 
with different ratio such as, First order release kinetics, Higuchi, Krosmeyer, Hixoncrowell plot, 
and also be noted the MDT calculation for improving the solubility of glimepiride. Formulations 
were characterized by Fourier transform infrared (FTIR) and X-ray diffraction (XRD). No any 
chemical interaction was observed between polymer and drugs from IR spectrum. The drug was 
changed to amorphous form after solid dispersion. Itwas also evident that solid dispersions 
improve solubility of drug particles thus enhancing dissolutioncharacteristics of drugs they 
increase the oral bioavailability. 
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Introduction 
Ithas studied that, improving oral bioavailability of drugs those given as solid dosage forms 
remains achallenge for the formulation scientists due to solubility problems. Most of the newly 
inventedchemical entities are poorly water soluble. As a result formulating them as oral solid 
dosage formsis a hurdle to the specialists. Many techniques have been exercised to improve oral 
bioavailabilityof drugs(1).The rate of dissolution and solubility should not be confused as they 
are different concepts, kinetic and thermodynamic, respectively. The solubilization kinetics, as 
 well as apparent solubility can be improved after complexation of an active ingredient with 
cyclodextrin. This can be used in the case of drug with poor solubility(2).The oral route of 
administration is the most preferred and widely acceptable route of delivery due to ease of 
ingestion for many drugs. Drugs with slow dissolution rate show the incomplete absorption 
leading to low bioavilability when orally administered (3). Many of the drugs belong to class II 
of the biopharmaceutical classification system showing poor solubility and high permeability 
Glimepiride shows low, pH dependent solubility. In acidic and neutral aqueous media, 
glimepiride exhibits very poor solubility at 370
o
c (<0.004 mg/ml). In media pH>7, solubility of 
drug is slightly increased to 0.02 mg/ml. These poorly water soluble drugs provide challenges to 
deliver them in an active and absorbable form to the desired absorption site using physiologically 
safe excipients Therefore, one of the most important steps in the development of dosage forms 
for these drugs is to improve their solubility and/or dissolution rate. Chiou and Rigelman and 
Serajuadin et al. have used the solid dispersion (SD) technique for dissolution enhancement of 
poorly water-soluble drugs (4). Among the various approaches, the SD technique has often 
proved to be the most successful in improving the dissolution and bioavailability of poorly 
soluble active pharmaceutical ingredients because it is simple, economic, and advantageous. 
Sekiguchi and Obi were the first to propose the SD method using water-soluble carriers to 
improve the dissolution characteristics of poorly water-soluble drugs. Many water-soluble 
carriers have been employed for preparation of SD of poorly soluble drugs(5). The most 
common are polyethyleneglycols, polyvinyl pyrrolidone, mannitol and hydroxypropyl 
methylcellulose. Due to poor solubility in GI fluids, it results in low and erratic oral 
bioavailability(6). Glimepiride was selected as a model drug for dissolution enhancement studies 
in the present investigation. Attempts were made to enhance the dissolution of GMP using a SD 
technique. SDs of GMP with PVP K 30 was prepared in different ratios using solvent 
evaporation method and then tablets of best formulation of SD were formulated by using direct 
compression method (7). Tablet formulations were prepared by direct compression technique 
using super disintegrates povidone in different concentrations. SDs were evaluated for FTIR, 
XRD, SEM, in vitro dissolution profiles and developed tablet formulations were evaluated for 
various pharmaceutical characteristics viz. hardness, % friability, weight variation, drug content, 
disintegration time, in vitrodissolution profiles (8). Priyanka Shrestha, et al, has studied 
that,Glimepiride is a poorly water-soluble oral hypoglycemic drug exhibiting poor dissolution 
pattern (9). The purpose of this work is to increase the dissolution rate of glimepiride by 
formation of solid dispersion with different water soluble carriers. Solid dispersion of 
glimepiride were prepared with polyvinyl pyrrolidone k-30, poloxamer 407, polyethylene glycol 
6000 (PEG 6000), polyethylene glycol 4000 (PEG 4000), sodiumstarch glycolate, ludiflash and 
lactose at different weight ratios using the solvent evaporation and melting method(10). Physical 
 mixtures of the poloxamer 407 and povidone K-30 with glimepiride at different ratios were also 
used. In compare to physical mixtures with povidone K-30 and poloxamer 407, drug release 
from physical mixture PM (1/9) PVP K-30 was higher (65.93% within 5 min) than drug release 
from physical mixture with poloxamer 407 (56% within 5 min) the drug release from pure drug 
was 6.84% with in 5 minute(11). With the recent development in the screening of potential therapeutic 
agents, the number of poorly water soluble drugs have risen sharply and gained large interest due to the 
challenges in the oral solubility of the drug which leads to the major cause for which the techniques are 
meant to be implemented. One amongst such techniques is the formulation of solid dispersion for the 
solubility enhancement(12). 
Materials and Methods: 
 
Chemicals Used 
Table 1: List of ingredients used in experiment 
 
Name of the materials Functional category Sources of the chemicals 
Glimepiride powder Active pharmaceutical 
ingrident  (API) 
ESKAYEF 
BANGLADESH LTD, 
GAZIPUR. 
Polyethylene glycol 
4000(PEG 4000) 
Carrier for solid dispersion ALBION 
LABOROTORIES LTD. 
Polyethylene glycol 
6000(PEG 6000) 
Carrier for solid dispersion ALBION 
LABOROTORIES LTD. 
PVP(Polyvinyl 
pyrrolidone) 
Carrier for solid dispersion LOCAL MAEKET 
Eudragit Carrier for solid dispersion THE ACME 
LABORATORIES LTD. 
Poloxomer 407 Carrier for solid dispersion BASF 
Potassium dihydrogen 
phosphate  
 
Major salt of buffer 
solution 
MERCK, MUMBAI. 
Di-sodium hydrogen 
phosphate 
Major salt of buffer 
solution 
MERCK, MUMBAI. 
Methanol  
 
Aqueous Solvent UNIVERSITY 
LABORATORY 
 
 
 Distilled water Solvent for buffer solution, 
used as washing agent too. 
UNIVERSITY 
LABORATORY 
 
 Fusion Method 
Fusion method of solid dispersion of glimepiride is given below: 
1. Desired amount out of drug and polymer were weighted out accurately e.g. PEG 4000 
2. They were taken in a beaker 
3. And placed it into water bath for melting at 70 0c. 
4. After melting, accurately weighted amount of drug was added in that glass beaker 
containing PEG 
5. Then they were mixed by glass rod to obtain a viscous mass.  
6. The mixture was stirred vigorously for uniform mixing and was kept in normal room 
temperature for 72 hour until a solid mass was formed. 
7. Solidified mixture was then grinded thoroughly with the help of mortar and pestle. 
8. Then the powdered particle passed through a sieve (mesh size 40). 
9. The resulted samples (Solid dispersion) were weighted and transferred in a fresh vial with 
proper labeling. 
10. Finally, the SD formulation were kept in a desiccator until further investigation.  
 
Table 2: Formulation of binary and ternary solid dispersion of glimepiride prepared by 
fusion method using different polymer at different ratio 
Serial 
no 
Carriers Drug  
polymer ratio 
Summarized form Dispensing(mg) Formulation 
coating 
Method 
1 PEG4000 1:1 Glim:PEG4000 300:300 G1 Fusion method 
2 PEG4000 1:2 Glim:PEG4000 300:600 G2 Fusion method 
3 PEG4000 1:3 Glim:PEG4000 300:900 G3 Fusion method 
4 PEG4000 1:4 Glim:PEG4000 300:1200 G4 Fusion method 
5 PEG4000 1:5 Glim:PEG4000 300:1500 G5 Fusion method 
6 PEG6000 1:1 Glim:PEG6000 300:300 G6 Fusion method 
7 PEG6000 1:2 Glim:PEG6000 300:600 G7 Fusion method 
8 PEG6000 1:3 Glim:PEG6000 300:900 G8 Fusion method 
9 PEG600 1:4 Glim:PEG6000 300:1200 G9 Fusion method 
10 PEG6000 1:5 Glim:PEG6000 300:1500 G10 Fusion method 
 
11 PEG4000:G
LM:POVID
ON 
1:1:0.75 PEG4000:G11:PO
VIDON 
200:200:150 G11 Fusion method 
12 PEG4000:G
LM:POVID
ON 
1:1:0.50 PEG4000:G12:PO
VIDON 
200:200:100 G12 Fusion method 
13 PEG4000:G
LM:POVID
ON 
1:1:0.25 PEG4000:G13:PO
VIDON 
200:200:50 G13 Fusion method 
14 PEG4000:G
LM:POVID
ON 
1:1:00 PEG4000:G14:PO
VIDON 
200:200:00 G14 Fusion method 
15 PEG6000:G
LM:POVID
ON 
1:1:0.75 PEG6000:G15:PO
VIDON 
200:200:150 G15 Fusion method 
66 PEG60000:
GLM:POVI
DON 
1:1:0.50 PEG6000:G16:PO
VIDON 
200:200:100 G16 Fusion method 
37 PEG600:G
LM:POVID
ON 
1:1:0.25 PEG6000:G17:PO
VIDON 
200:200:50 G17 Fusion method 
38 PEG600:G
LM:POVID
ON 
1:1:00 PEG6000:G18:PO
VIDON 
200:200:00 G18 Fusion method 
 
 
 
 
Preparation of 0.01 M phosphate buffer solution (pH=7.8) 
0.58g of monobasic potassium phosphate and 8.86g of dibasic sodium phosphate anhydrous was 
dissolved in sufficient amount of distilled water. Then pH 7.8 was adjusted by adding 1N 
Sodium Hydroxide (NaOH) for the preparation of 1000ml buffer solution. 
 Preparation of Standard Curve of Glimepiride 
1. 10mg of Glimepiride was accurately weighed and taken in 100ml volumetric flask. 
2. Then phosphate buffer was added upto the mark to prepare primary stock solution.  
3. Then 10 ml of this solution was taken in another100ml volumetric flask and added buffer 
solution up to the mark. This solution was called stock solution. 
4. Then serial dilution was carried out to get different drug concentration. 
5. Then 1,2,3,4,5,6,7,8,9 and 10ml of stock solution was gradually taken to the test tube. 
 6. And 9,8,7,6,5,4,3,2,1 and o ml of buffer solution were added respectively to more 10 ml 
volume in each test tube.  
7. These were then analyzed by UB spectrophotometer at 228 nm and the absorbance value 
were noted. 
8. The absorbance value were plotted against drug concentrations. 
9. Finally the standard curve of Glimepiride was produced.  
 
 In-vitro dissolution test for Glimepiride and solid dispersion formulation 
The in vitro dissolution studies for Glimepiride drug and SD formulation were performed 
using USP dissolution test apparatus type II (paddle type) method using 900 ml of 
phosphate buffer (pH 7.8) as dissolution medium. The temperature of the medium was 
maintained at (37 ± 0.5)
o
c throughout the experiment. The samples contained glimepiride 
or its equivalent solid dispersion were placed in the dissolution medium. Paddle was used 
at a stirring rate of 75 rpm. A 5ml aliquot was withdrawn at predetermined time intervals 
of 5,15,30.45, and 60 min and then 5ml of fresh dissolution medium was replaced to 
maintain the constant volume of dissolution medium. The absorbance values of the 
collected samples was measured at 273nm using UV-visible spectrophotometer against 
dissolution medium as blank. The percent release of drug was calculated using the 
equation obtained from the standard curve in the media.    
[15]
. 
 
 
 
 Fourier transform Infra-red (FTIR) Spectroscopy 
Infra-red studies was carried out to rule out interaction between drug and carrier used in 
formulation of solid dispersion by potassium bromide disc method using Infra-red 
spectrophotometer. FT-IR spectroscopy used to study the possibility of an interaction between 
drug and polymer in solid-state. 
Fourier-transform infrared (FT-IR) spectra were obtained by using a Shimadzu IR 20 
Spectrophotometer. The samples (Glimepiride or SDs) were previously grounded and mixed 
thoroughly with potassium bromide, an infrared transparent matrix, at 1:5 (Sample: KBr) ratio, 
respectively. The KBr discs were prepared by using corresponding machine. Scans were 
obtained at a resolution of 4 cm-1, at wave numbers from 4000 to 500 cm -1. 
 
Results and Discussion  
 
 Glimepiride is an oral blood sugar-lowering drug in a class of medicine for controlling diabetes 
called Sulfonylurea. The aims of present investigation was to enhance the dissolution rate of 
poorly water soluble drugs glimepiride by preparing the solid dispersion using poloxomer 407, 
povidon, PEG 4000, PEG 6000. In this study solvent evaporation method and fusion/melting 
method was used for the preparation of solid dispersion of glimepiride. 
 
 Standard curve of glimepiride (Media: Phosphate buffer, pH 7.8) 
 
 
                      Fig: 18 Standard curve of glimepiride 
 
 Dissolution profile of active Glimepiride 
 
10 mg of pure Glimepiride was used for dissolution study. It was found that only 0.46% drug 
was released after 5 minutes and 15.83% was released within 60 minutes time interval. This 
showed that dissolution profile of glimepiride was very poorly. 
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Fig: 2Dissolution profile of glimepiride (API) 
 
In vitro dissolution study of binary and ternary solid dispersion of glimepiride 
(fusion method)  
 Comparative dissolution profile of active glimepiride and solid dispersion (SD) 
formulation (Glimepiride+PEG 4000) for their different ratio 
 
Solid dispersion of glimepiride with PEG 4000 at different ratio G1 (1:1), G2 (1:2), G3 (1:3), G4 
(1:4), G5 (1:5) and active glimepiride (API) were used for dissolution study. It was found that 
only 0.46% from active glimepiride, 21.46% from formulation G1, 56.30% from G2, 77.30% 
from G3, 64.15% from G4 and 76.84% from G5, were released after 5 min and 60.77% from G1, 
83.66% from G2, 88.83% from G3, 65.47% from G4, 94.36% from G5, 15.29% from active 
glimepiride were released after 45min. Finally 72.88% from G1, 97.27% from G2, 90.91% from 
G3, 75.75% from G4, 99.76% from G5 were released within an hour time interval. Whereas only 
15.83% was released from active glimepiride within an hour time interval.  
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 Fig: 3. Average % release of drug from binary SD formulation containing PEG 4000 with 
different ratio 
  
From the above data we can conclude that, the release pattern of drug from SD formulation 
containing PEG 4000 has increased gradually when the amount of PEG 4000 was increased. It 
was observed that solid dispersion formulation G5 showed substantially better result in 1:5 ratio 
in comparison to those of G1, G2, G3, and G4. 
 
 Comparative dissolution profile of active glimepiride and solid dispersion formulation 
(Glimepiride + PEG 6000) for their different ratio. 
Solid dispersion of glimepiride with PEG 6000 at different ratio G6 (1:1), G7 (1:2), G8 (1:3), G9 
(1:4), and G10 (1:5) were used for dissolution study. It was found that 24.46% from G6, 37.86% 
from G7, 25.84% from G8, 38.53% from G9, 53.76% from G10 were released after 5 min and 
60.36% from G6, 68.30% from G7, 70.72% from G8, 50.28% from G9, and 64.82% from G10 
were released after 45min. Finally 71.31% from G6, 88.99% from G7, 91.87% from G8, 51.01% 
from G9 and 49.71% from G10 were released within an hour time interval. 
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Fig: 4. Average % release of drug from SD formulation containing PEG 6000 with 
different ratio 
From the above data it was found that, the release pattern from SD formulation containing PEG 
6000 has increased gradually when the amount of PEG 6000 was decreased. It was observed that 
solid dispersion formulation G8 showed their better result in 1:3 ratios in comparison to those of 
G6, G7, G9, and G10. 
 
 Comparative dissolution profile of active glimepiride and solid dispersion (Glimepiride+ 
PEG 4000+ Povidon) for their different ratio 
Ternary SD formulation of Glimepiride containing PEG 4000 and Povidon at different ratios of 
G11 (1:1:0.75), G12 (1:1:0.50), G13 (1:1:0.25), G14 (1:1:0) and API were used for dissolution 
study. It was found that 6% from G11, 1.38% from G12, 64.15% from G13, 21.46% from G14 
and 0.46% from API were released after 5 min and 11.48% from G11, 14.19% from G12, 
65.47% from G13, 60.77% from G14, 15.29% from API were released after 45 min. Finally 
24.69% from G11, 19.35% from G12, 75.75% from G13, 72.88% from G14 and 15.83% from 
API were released in an hour time interval. 
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 Fig: 5 Average % release of drug from ternary SD formulation containing PEG 4000 and 
Povidone. 
From the above data we can conclude that the release pattern from the glimepiride containg two 
water soluble polymer PEG 4000 and Povidone have increased gradually when the amount of 
second polymer povidone were decreased in different ratio. It was observed SD formulation G13 
(1:1:0.75) gave the best result in comparison to those of G11, G12, G14. 
 
Comparative dissolution profile of pure glimepiride and solid dispersion formulation 
(Glimepiride+ PEG 6000+ Povidone) for their different ratio 
Ternary SD formulation of Glimepiride containing PEG 6000 and Povidone at different ratio of 
G15 (1:1:0.75), G16 (1:1:0.50), G17 (1:1:0.25), G17 (1:1:0) and API were used in dissolution 
study. It was found that 63.46% from G15, 63.92% from G16, 23.90% from G17, 24.46% from 
G18 and 0.46% from API were released after 5 min and 73.71% from G15, 69.14% from G16, 
61.84% from G17, 60.36% from G18, 15.29% from API were released after 45 min. Finally 
75.50% from G15, 72.06% from G16, 69.09% from G17, 71.31% from G18 and 15.83% from 
API were released in an hour interval. 
 
 
Fig: 6 Percent release from ternary SD formulations of glimepiride containing  
PEG 6000 and Povidone. 
From the above data we can conclude that the release pattern from the glimepiride containg two 
water soluble polymer PEG 6000 and Povidone has increased gradually when the amount of 
second polymer povidone were increased in different ratio. It was observed SD formulation G15 
(1:1:0.75) gave the best result in comparison to those of G16, G17, G18. 
 
 Release kinetics study of pure glimepiride and different solid dispersion 
formulations  
We have chosen five SD formulation G5 (Glim + PEG 4000), G8 (Glim + PEG 6000), G13 
(Glim+ PEG 4000 + Povidone), SE2 (Glim + Eudragit), SE9 (Glim + Poloxamer), which were 
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 given most significant effect on the improvement of dissolution rate. There dissolution data were 
analyzed by zero order model, First order, Higuchi square root equation, Hixon crowell cube root 
law and Krosmeyer Kinetics. 
 Zero order kinetics 
Table 3 Comparative study of zero order kinetics of five solid dispersion formulations 
Time 
Percent release 
(%) G5 
Percent release 
(%)G8 
Percent 
release (%)G13 
0 0 0 0 
5 76.84615 25.84615 64.15385 
15 80.73462 26.22051 61.04872 
30 89.02692 50.36538 71.77051 
45 94.36282 70.72051 65.47308 
60 99.2641 91.87949 75.75385 
 
 
 
First order release kinetics 
Table 4: Comparative study of first order release kinetics of active glimepiride and five 
solid dispersion formulations 
Time 
(min) 
Log of % 
remaining 
drug(G5) 
Log of % 
remaining 
drug (G8)  
Log of % 
remaining 
drug(G13) 
Log of % 
remaining 
drug(API) 
0 2 2 2 2 
5 1.364623 1.870134 1.554443 1.997991 
15 1.284778 1.867936 1.590522 1.989849 
30 1.040328 1.695785 1.450703 1.963352 
45 0.751062 1.466564 1.538158 1.927929 
60 -0.13318 0.909583 1.384643 1.92512 
 
 
 
 
 Higuchi release kinetics 
Table 5: Comparative study of Higuchi release kinetics of active glimepiride and five solid 
dispersion formulations 
  
 
 
 
 
 
 Hixon crowell release 
kinetics 
Table 6. Comparative 
study of Hixon crowell release kinetics of active glimepiride and five solid dispersion 
formulations 
Time 
(min) 
Cubic root of 
% remaining 
drug (G5) 
Cubic root of 
% remaining 
drug(G8) 
Cubic root of 
% remaining 
drug (G13) 
Cubic root of 
% remaining 
drug (API) 
     
0 4.641589 4.641589 4.641589 4.641589 
5 2.850194 4.201244 3.297217 4.634437 
15 2.680768 4.194162 3.389799 4.605566 
30 2.222164 3.675036 3.044862 4.512847 
45 1.779729 3.082155 3.256262 4.391806 
60 0.90283 2.009992 2.894327 4.382347 
 
 
 Krosmeyer release kinetics 
Table 7: Comparative study of korsmeyer release kinetics of active glimepiride and five 
solid dispersion formulations 
 
Log 
time=Log 
T 
Log fraction of 
drug 
release=log( % 
release/100)G5 
Log fraction of 
drug 
release=log( % 
release/100)G8 
Log fraction of 
drug 
release=log( % 
release/100)G13 
Log fraction of 
drug 
release=log( % 
release/100)API 
0.69897 -0.11438 -0.5876 -0.19278 -2.33579 
1.176091 -0.09294 -0.58136 -0.21432 -1.63634 
1.477121 -0.05048 -0.29787 -0.14405 -1.09193 
     
Square root 
of time 
(SQRT) 
%release of 
drug(G5) 
%release of 
drug(G8) 
% release of 
drug(G13) 
% release of 
drug(API) 
0 0 0 0 0 
2.236068 76.84615 25.84615 64.15385 0.461538 
3.872983 80.73462 26.22051 61.04872 2.310256 
5.477226 89.02692 50.36538 71.77051 8.092308 
6.708204 94.36282 70.72051 65.47308 15.29103 
7.745967 99.2641 91.87949 75.75385 15.83718 
 1.653213 -0.0252 -0.15045 -0.18394 -0.81556 
1.778151 -0.00321 -0.03678 -0.1206 -0.80032 
 
 
 
 
 Successive fractional dissolution time  
Table 8: Table for Mean Dissolution Time (MDT) calculation  
Formulation Code T25% T50% T80% MDT 
Pure Drug 69.89354 110.7925 151.4168 105.5033 
G5 0.000124 0.100156 9.39399 7.609336 
G8 0.115755 0.427337 1.036083 0.546968 
G13 7.09E-07 0.124536 448.1191 1186.845 
 
 
 
Mean dissolution time (MDT) value was used to characterized the drug release rate form the 
dosage forms and the retarding efficiency of the polymer. Form the above Table 8, it was found 
that, a higher MDT value for the SD formulation G13 ( glimepiride + PEG 4000 + Povidone) 
which was indicated that higher drug retarting ability of the polymer in the formulation. 
 
 
 
 
 
 
 
 
Interpretation of Y equation  ( Y= ax + b) and correlation co efficient ( R
2
) 
value for different release kinetics of active glimepiride and SD formulation 
Table: 9 Y equation and R
2
 values of five SD formulations and active glimepiride  
 Formulati
on coding 
Zero Order 1
st
 Order Kinetics Higuchi model Hixon Crowell model 
 Y equation R
2 
Value Y 
equation 
R
2 
Value Y equation R
2 
Value Y equation R
2 
Value 
Pure drug 0.3007x-
0.77 
 0.957   -
0.0041x+
2.0041 
  0.955  2.3177x+3.06
03 
 0.861 -
0.0049x+4.6
553 
 0.956 
G5 1.1172x+4
4.512 
 0.508  -
0.0288x+
1.7956 
 0.903  11.038x+25.4
68 
 0.751  -
0.0484x+3.7
632 
 0.822 
G8  1.401x+7.
9786 
 0.966  -
0.0161+2.
0509 
 0.896  11.22x-
4.5245 
0.939 -
 0.0396x+4.
6578 
 0.947 
G13  0.7739x+
22.763 
 0.419  -
0.0067x+
1.7584 
 0.525 7.8884x+22.1
3 
0.66  -
0.0185x+3.8
993 
 0.487 
 
The above data showed that R
2
 value of active glimepiride, (R
2 
= 0.957) and SD formulation G8 
(R
2
 = 0.966) were found substantially highest result in case of Zero order kinetics than other 
release kinetics. These R
2
 value is near about 01, so it can be said that, active glimepiride, SD 
formulation G8 were followed zero order release pattern. 
Another SD formulation G13 (R2= 0.66) was displayed best fitting with Higuchi release kinetics 
pattern. Because R
2
value of G13 was showed better value in case of Higuchi release kinetics. 
Only one SD formulation G15 was best fitted with first order release pattern. 
It was also observed that, in all case no formulation was fitted with Hixon Crowell kinetics 
model. 
Glimepiride & polymer interaction study using FT-IR Spectroscopy: 
Fourier Transform Infrared Spectroscopic (FTIR) study was concluded four samples- 
1.Pure drug/API (Glimepiride) 
2. Polymer (PEG 4000) 
3. Polymer (Poloxamer 407) 
4. Solid Dispersion (G3=Glimipiride+PEG4000, 1:3) 
5. Solid Dispersion (G13=Glimepiride+Povidone+PEG 4000, 1:5) 
 
FT-IR was used to characterize possible interactions between the drug and the carrier in solid 
Diclofenac Sodium. 
 
FT-IR spectra of Pure Glimepiride 
  
 
 
 
 
 
 
 
 
 
 
 
 
SN. Peak Indication 
01 1454.39 cm
-1 
1444.75 cm
-1 
1437.03 cm
-1 
C-H bending 
 02 1659.82 cm
-1 
C=C Stretching 
03 1595.20 cm
-1 
C=O Asymmetric Stretching   
04 1345.41 cm
-1 
C-N Stretching 
05 1317.44 cm
-1 
S=O Asymmetric Stretching 
06 1150.59 cm
-1 
S=O Symmetric Stretching 
 
07 1472.71 cm
-1 
NH2 bending 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FTIR spectra of Glimepiride Solid dispersion with PEG4000 prepared by 
Fusion method (G3=Glim+PEG4000) 
  
Fig: 4. FTIR of G3 (Glim+PEG4000) 
 
 
 
 
 
 
 
 
 
 
 
SN. Peak Indication 
01 1150.59 cm
-1
 C=O (stretch) 
02 1360.84 cm
-1
, 
1465.96 cm
-1
, 
C-H (bending) 
 1472.71 cm
-1, 
03 1671.39 cm
-1 
C=C (Stretch) 
04 1671.39 cm
-1
, 
1696.47 cm
-1
, 
1706.11 cm
-1, 
C=O (Stretch), Carbonyl 
05 1242.21 cm
-1
, 
1279.82 cm
-1
, 
C-O (Stretch), Acid 
06 1706.11 cm
-1 
Acyclic (Stretch), Ketone 
 
From the above shown spectrum, we came to conclude that the spectrum seen in the pure 
glimepiride was also found in the case of solid dispersion with PEG4000. The spectrum were at 
same frequency range but some peaks were shifted to their near values. So we can say that there 
is no significant interaction between the drug & PEG4000, hence there was no chemical change 
in the PEG4000 when it was in solid dispersion form. 
 
 
 
 
 
 
 
 
 
 
 FTIR spectra of Glimepiride Solid dispersion with PEG4000 & Povidon 
prepared by Fusion method (G13= Glim+PEG4000+Povidon) 
 
  
Fig: 5 FTIR of G13 (Glim+PEG4000+Povidone) 
 
 
 
 
 
 
 
 
 
SN. Peak Indication 
01 1060.89 cm-1, 
1079.22 cm
-1
, 
1150.59 cm
-1
, 
C-O (Stretch) 
02 1360.84 cm
-1
, 
1394.59 cm
-1
, 
-C-H (bending) 
 1437.03 cm
-1
, 
1456.32 cm
-1
, 
1465.00 cm
-1
, & 
14.72.71 cm
-1, 
03 687.65 cm
-1
, 
841.96 cm
-1
, 
949.98 cm
-1
, 
963.98 cm
-1
, & 
1000.13 cm
-1 
=C-H (Stretch) 
04 1437.03 cm
-1
, 
1456.32 cm
-1
, 
1465.00 cm
-1
,  
14.72.71 cm
-1,
& 
1595.20 cm
-1 
C=C (Stretch) 
 
From the above shown spectrum, we came to conclude that the spectrum seen in the pure 
glimepiride was also found in the case of solid dispersion with PEG4000 & Povidone. The 
spectrum were at same frequency range but some peaks were shifted to their near values. So we 
can say that there is no significant interaction between the drugs, PEG4000, & Povidone, hence 
there was no chemical change in the PEG4000, and Povidone, when it was in solid dispersion 
form. 
 
 
 
 
 
 
 
 
 
 
Conclusion 
Solid dispersion has attracted considerable interest as an efficient means of improving the 
dissolution rate and bioavailability of hydrophobic drugs. In the present study, solid dispersions 
 of Glimepiride with different hydrophilic carriers in different ratios were prepared by physical 
mixing and fusion method to improve water solubility and dissolution characteristics. The 
preparation of solid dispersion of Glimepiride by fusion method has been proven to be 
successful. This research showed that when Glimepiride was dispersed in suitable water-soluble 
carriers such as PEG 6000, PEG 4000 and Eudragit E-100, Poloxomer 407 and Povidone. Its 
dissolution were enhanced compared with pure drug. Fusion method of the poloxamer 407 and 
Eudragit with glimepiride at different ratios were also used. It was found the drug was released 
0.46% after 5 minutes and only 15.83% within 60 minutes from active glimepiride on the other 
hand the release pattern of glimepiride from the binary formulation containing PEG 4000 in 1:5 
(Formulation coding: G5) showed the best result. It was found that the ternary different SD 
formulation containing (PEG4000: Glimepiride:Povidon) in ratio 1:1:0.25 (Formulation coding 
were : G13) showed the best result. It was also studied that the release kinetics of glimepiride of 
different SD formulation with different ratio such as, First order release kinetics, Higuchi, 
Krosmeyer, Hixon crowell plot, and also be noted the MDT calculation for improving the 
solubility of glimepiride.. In-vitro dissolution data also proves that percent release of drug from 
binary SDs was not similar with ternary SDs. Ternary SDs is more effective to increase the 
diclofenac sodium release rate. The water soluble carrier may operate in the micro environment 
(diffusion layer) immediately surrounding the drug particles in the early stage of dissolution, 
since the carrier completely dissolves in short time thus enhancing the solubility & dissolution of 
drug.  
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